GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Equity-to-Asset

NKTX (Nkarta) Equity-to-Asset : 0.81 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nkarta Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nkarta's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $430.87 Mil. Nkarta's Total Assets for the quarter that ended in Sep. 2024 was $532.03 Mil.

The historical rank and industry rank for Nkarta's Equity-to-Asset or its related term are showing as below:

NKTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.92   Med: 0.79   Max: 0.95
Current: 0.81

During the past 6 years, the highest Equity to Asset Ratio of Nkarta was 0.95. The lowest was -1.92. And the median was 0.79.

NKTX's Equity-to-Asset is ranked better than
67.79% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs NKTX: 0.81

Nkarta Equity-to-Asset Historical Data

The historical data trend for Nkarta's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Equity-to-Asset Chart

Nkarta Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -0.53 0.95 0.92 0.79 0.72

Nkarta Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.72 0.82 0.82 0.81

Competitive Comparison of Nkarta's Equity-to-Asset

For the Biotechnology subindustry, Nkarta's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nkarta's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Nkarta's Equity-to-Asset falls into.



Nkarta Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Nkarta's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=273.285/378.885
=

Nkarta's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=430.873/532.034
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nkarta  (NAS:NKTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Nkarta Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Nkarta's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nkarta Business Description

Traded in Other Exchanges
N/A
Address
1150 Veterans Boulevard, South San Francisco, CA, USA, 94080
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Executives
Alicia J. Hager officer: Chief Legal Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Paul J Hastings director, officer: See Remarks 61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook officer: Chief Medical Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Ralph Brandenberger officer: Sr. VP, Technical Operations 6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager officer: Chief Scientific Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alyssa Levin officer: See Remarks 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood officer: Chief Business Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Angela Thedinga director C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam officer: Chief Medical Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900